secwatch.observer — SEC 8-K summary
======================================

Issuer:     Vivani Medical, Inc. (VANI)
CIK:        0001266806
Form:       8-K
Filed at:   2024-06-13T23:59:59+00:00
Accession:  0001753926-24-001110
Event type: regulatory
Sentiment:  positive
Materiality: 0.70
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

FDA lifts clinical hold on Vivani Medical's NPM-119, clears IND for Phase 1 trial
--------------------------------------------------------------------------------

- FDA cleared IND and lifted clinical hold for NPM-119 (exenatide), a six-month GLP-1 implant for type 2 diabetes.
- LIBERATE-1 Phase 1 trial will assess safety, tolerability, and pharmacokinetics vs. Bydureon BCise; enrollment expected H2 2024.
- First clinical application of NanoPortal implant technology; addresses medication non-adherence affecting ~50% of type 2 diabetes patients.
- Lead program NPM-115 (high-dose exenatide) for chronic weight management showed preclinical weight loss comparable to semaglutide.
- NPM-139 (semaglutide implant) in pipeline with potential once-yearly dosing.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1266806/000175392624001110/0001753926-24-001110-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1266806/000175392624001110/g084283_8k.htm
  HTML page:      https://secwatch.observer/filing/0001753926-24-001110

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer